Incyte Genomics of Palo Alto, Calif., and Eli Lilly of Indianapolis have expanded an agreement to collaborate on accelerating the development of therapeutic proteins. Under the terms of the new agreement, Eli Lilly and Incyte will focus on identifying and selecting secreted molecules that are strong candidates for therapeutic protein development. Eli Lilly will also obtain options to license multiple therapeutic protein patents from Incyte.
Financial terms of the deal were not disclosed.
Over the last three years, Lilly has used Incyte’s LifeSeq Gold database in its drug discovery and development efforts.
Incyte has more than 500 issued and allowed patents on full-length genes, including 134 issued patents on therapeutic proteins.